Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04984356 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL
A Phase 1 study, sponsored by Wugen.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT04984356 is a Phase 1 study that has completed, run by Wugen. The registered enrollment target is 28 participants.
The verdict
NCT04984356, a Phase 1 study, has completed, sponsored by Wugen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, recommended dose, and preliminary anti-tumor activity of WU-CART-007 in patients with relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (LBL).
Interventions
- BIOLOGICAL WU-CART-007
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2022-01-14 |
| Est. Completion | 2024-08-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04984356
The ClinicalTrials.gov registry entry for NCT04984356 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wugen, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which WU-CART-007 is the first listed.
NCT04984356 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04984356 about?
NCT04984356 is a clinical study titled "A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL". The purpose of this study is to evaluate the safety, recommended dose, and preliminary anti-tumor activity of WU-CART-007 in patients with relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (LBL).
What is the current status of trial NCT04984356?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2022-01-14. Estimated completion is 2024-08-08.
What interventions are being tested in trial NCT04984356?
The interventions under investigation include: WU-CART-007 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04984356?
This trial is sponsored by Wugen, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.